Singapore: US-based Amgen enters the Asian market with its new 'next-generation' biomanufacturing facility in Singapore. The plant is located in Tuas Biomedical Park. It will maufacture a medicinal substance used in the treatment of bone conditions such as osteoporosis. The company also plans to build a second facility on the same site to produce an active ingredient used for treating patients with multiple myeloma.

According to the company, the facility encompasses multiple technologies to enable greater speed, productivity and flexibility in commercial-scale manufacturing.

"We are reinventing what it means to manufacture biologic medicines and Singapore is an ideal place to invest in such a pioneering facility," said Mr Robert Bradway, Amgen's chief executive.